Strategic Initiative

Slingshot members are tracking this corporate initiative:

Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave (naltrexone HCl / bupropion HCl extended release)

Source Link:: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=2198179

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

OREX

100%

VRX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Orexigen will supply Contrave tablets to Valeant Canada or its affiliates for an agreed transfer price and certain potential regulatory and sales milestone payments. Orexigen expects Valeant to file with Health Canada for regulatory approval by January 2017.

http://ir.orexigen.c...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Aug 30, 2016

Projected Implementation:

Q3, 2017

Relevance Tracked Until:

Q4, 2017

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Contrave, Naltrexone Hci, Bupropion Hci Extended Release